Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results

Gooitzen M. van Dam; George Themelis; Lucia M. A. Crane; Niels J. Harlaar; Rick G. Pleijhuis; Wendy Kelder; Athanasios Sarantopoulos; Johannes S. de Jong; Henriette J. G. Arts; Ate G. J. van der Zee; Joost Bart; Philip S. Low; Vasilis Ntziachristos

doi:10.1038/nm.2472

Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results

Gooitzen M. van Dam^*, George Themelis, Lucia M. A. Crane, Niels J. Harlaar, Rick G. Pleijhuis, Wendy Kelder, Athanasios Sarantopoulos, Johannes S. de Jong, Henriette J. G. Arts, Ate G. J. van der Zee, Joost Bart, Philip S. Low, Vasilis Ntziachristos

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

1346 Citations (Scopus)

Abstract

The prognosis in advanced-stage ovarian cancer remains poor. Tumor-specific intraoperative fluorescence imaging may improve staging and debulking efforts in cytoreductive surgery and thereby improve prognosis. The overexpression of folate receptor-alpha (FR-alpha) in 90-95% of epithelial ovarian cancers prompted the investigation of intraoperative tumor-specific fluorescence imaging in ovarian cancer surgery using an FR-alpha-targeted fluorescent agent. In patients with ovarian cancer, intraoperative tumor-specific fluorescence imaging with an FR-alpha-targeted fluorescent agent showcased the potential applications in patients with ovarian cancer for improved intraoperative staging and more radical cytoreductive surgery.

Original language	English
Pages (from-to)	1315-U202
Number of pages	6
Journal	Nature Medicine
Volume	17
Issue number	10
DOIs	https://doi.org/10.1038/nm.2472
Publication status	Published - 18-Sept-2011

Keywords

BREAST-CANCER
MANAGEMENT
SURGERY
EXPRESSION
STRATEGIES
SURVIVAL
FUTURE
TISSUE
MODEL

Access to Document

10.1038/nm.2472

Handle.net

Persistent link

Embargoed Document

Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting
Final publisher's version, 1.19 MB

Cite this

van Dam, G. M., Themelis, G., Crane, L. M. A., Harlaar, N. J., Pleijhuis, R. G., Kelder, W., Sarantopoulos, A., de Jong, J. S., Arts, H. J. G., van der Zee, A. G. J., Bart, J., Low, P. S., & Ntziachristos, V. (2011). Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. Nature Medicine, 17(10), 1315-U202. https://doi.org/10.1038/nm.2472

@article{c0295535dda448f184f30424d83e7d3f,

title = "Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results",

abstract = "The prognosis in advanced-stage ovarian cancer remains poor. Tumor-specific intraoperative fluorescence imaging may improve staging and debulking efforts in cytoreductive surgery and thereby improve prognosis. The overexpression of folate receptor-alpha (FR-alpha) in 90-95% of epithelial ovarian cancers prompted the investigation of intraoperative tumor-specific fluorescence imaging in ovarian cancer surgery using an FR-alpha-targeted fluorescent agent. In patients with ovarian cancer, intraoperative tumor-specific fluorescence imaging with an FR-alpha-targeted fluorescent agent showcased the potential applications in patients with ovarian cancer for improved intraoperative staging and more radical cytoreductive surgery.",

keywords = "BREAST-CANCER, MANAGEMENT, SURGERY, EXPRESSION, STRATEGIES, SURVIVAL, FUTURE, TISSUE, MODEL",

author = "{van Dam}, {Gooitzen M.} and George Themelis and Crane, {Lucia M. A.} and Harlaar, {Niels J.} and Pleijhuis, {Rick G.} and Wendy Kelder and Athanasios Sarantopoulos and {de Jong}, {Johannes S.} and Arts, {Henriette J. G.} and {van der Zee}, {Ate G. J.} and Joost Bart and Low, {Philip S.} and Vasilis Ntziachristos",

year = "2011",

month = sep,

day = "18",

doi = "10.1038/nm.2472",

language = "English",

volume = "17",

pages = "1315--U202",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

number = "10",

}

van Dam, GM, Themelis, G, Crane, LMA, Harlaar, NJ, Pleijhuis, RG, Kelder, W, Sarantopoulos, A, de Jong, JS, Arts, HJG, van der Zee, AGJ , Bart, J, Low, PS & Ntziachristos, V 2011, 'Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results', Nature Medicine, vol. 17, no. 10, pp. 1315-U202. https://doi.org/10.1038/nm.2472

TY - JOUR

T1 - Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting

T2 - first in-human results

AU - van Dam, Gooitzen M.

AU - Themelis, George

AU - Crane, Lucia M. A.

AU - Harlaar, Niels J.

AU - Pleijhuis, Rick G.

AU - Kelder, Wendy

AU - Sarantopoulos, Athanasios

AU - de Jong, Johannes S.

AU - Arts, Henriette J. G.

AU - van der Zee, Ate G. J.

AU - Bart, Joost

AU - Low, Philip S.

AU - Ntziachristos, Vasilis

PY - 2011/9/18

Y1 - 2011/9/18

N2 - The prognosis in advanced-stage ovarian cancer remains poor. Tumor-specific intraoperative fluorescence imaging may improve staging and debulking efforts in cytoreductive surgery and thereby improve prognosis. The overexpression of folate receptor-alpha (FR-alpha) in 90-95% of epithelial ovarian cancers prompted the investigation of intraoperative tumor-specific fluorescence imaging in ovarian cancer surgery using an FR-alpha-targeted fluorescent agent. In patients with ovarian cancer, intraoperative tumor-specific fluorescence imaging with an FR-alpha-targeted fluorescent agent showcased the potential applications in patients with ovarian cancer for improved intraoperative staging and more radical cytoreductive surgery.

AB - The prognosis in advanced-stage ovarian cancer remains poor. Tumor-specific intraoperative fluorescence imaging may improve staging and debulking efforts in cytoreductive surgery and thereby improve prognosis. The overexpression of folate receptor-alpha (FR-alpha) in 90-95% of epithelial ovarian cancers prompted the investigation of intraoperative tumor-specific fluorescence imaging in ovarian cancer surgery using an FR-alpha-targeted fluorescent agent. In patients with ovarian cancer, intraoperative tumor-specific fluorescence imaging with an FR-alpha-targeted fluorescent agent showcased the potential applications in patients with ovarian cancer for improved intraoperative staging and more radical cytoreductive surgery.

KW - BREAST-CANCER

KW - MANAGEMENT

KW - SURGERY

KW - EXPRESSION

KW - STRATEGIES

KW - SURVIVAL

KW - FUTURE

KW - TISSUE

KW - MODEL

U2 - 10.1038/nm.2472

DO - 10.1038/nm.2472

M3 - Article

C2 - 21926976

SN - 1078-8956

VL - 17

SP - 1315-U202

JO - Nature Medicine

JF - Nature Medicine

IS - 10

ER -

Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results

Abstract

Keywords

Access to Document

Handle.net

Embargoed Document

Fingerprint

Cite this